Damian Garde
@statnews biotech reporter, inventor of CRISPR | [email protected] | Signal/WhatsApp: 202-780-9154
Last synced from Twitter 804d ago
Can boosting the ‘bliss molecule’ help treat mental health conditions?
FAAH inhibitors have been tested in dozens of trials, only for each one to fail. But one company is going to give them another shot.
Investor Bill Gross accused of blaring ‘Gilligan's Island' song on loop to torment neighbor
A dispute between bond king Bill Gross and a neighbor over an outdoor sculpture has devolved into police calls to their Laguna Beach mansions and allegations that the billionaire investor blared the "Gilligan's Island" theme song on repeat.
1
Damian Garde
bless this story
36d
Blood plasma showed no benefit in Covid-19 patients in trial
The findings, published in BMJ, could re-energize the debate over whether blood plasma is an effective treatment for the disease.
Listen: How FDA thinks about Covid vaccines & biotech's SPAC fascination
This week, we discuss a momentous FDA meeting about Covid-19 vaccines and why its lack of fireworks is heartening to public health experts.
Listen: A big week for pausing studies & pharma's statehouse spending
This week, we discuss two high-profile pauses to Covid-19 clinical trials and explain why experts say they offer more good news than bad.
NIH paused Eli Lilly Covid-19 antibody trial because of safety concerns
Lilly had reported its antibody reduced the amount of virus in patients’ nasal swabs and may have kept some patients out of the hospital.
Covid-19 study pauses at J&J, Lilly could be hard bumps — or mere blips
Experts stress that clinical trial pauses are common — and even signs that the system is working as it should.
Selling stock at a clip, top Moderna doctor gets $1 million richer each week
Chief Medical Officer Tal Zaks has been selling his stock every Tuesday lately, earning him more than $50 million since the pandemic started.
Listen: How Trump's Covid-19 affects biotech, medicine, and the FDA
We unpack Trump's endorsement of Regeneron and his apparent acceptance that there won't be a Covid-19 vaccine before Election Day.
Celgene shareholders are parsing blurry photos in search of a payday
Images of what may not be FDA inspectors walking into what may or may not be a Celgene plant suddenly matter a great deal to some.
Trio wins Nobel Prize in medicine for discovery of hepatitis C virus - STAT
Harvey Alter of the NIH, Michael Houghton of the University of Alberta, and Charles Rice of the Rockefeller University share the prize.
1
Damian Garde
There was a time when hepatitis C was known as “non-A, non-B.” Three scientists who, among other things, knew the third letter of the English alphabet have now won a Nobel Prize
58d
Regeneron Covid-19 antibody may help speed recovery, early data show
Experts caution more data from larger trials will be needed to know how potentially beneficial monoclonal antibodies are.
2
Damian Garde
if you're curious how well the treatment Trump just got actually works, we got some interim data on that just this week
60d
It's time for STAT's 2020 Nobel Prize predictions - STAT
Focusing on science’s greatest hits to forecast the Nobel winners is too simplistic. The smart money looks for other criteria.
1
Damian Garde
why not spend a few minutes with @sxbegle gazing into the abyss that is predicting just who will win this years Nobel Prizes next week
61d
Listen: Risk for Covid-19 vaccine trials & intermittent fasting data disappoints
Yale University vaccine expert Saad Omer joins us to discuss how the side effects of Covid-19 vaccines could disrupt ongoing clinical trials.
STAT+ Conversations: How Covid-19 will change drug development - STAT
Industry leaders from the Covid-19 Research and Development Alliance discuss how the pandemic will change the future of drug development.
Listen: A road map for Covid-19 & the gold rush in health tech
STAT’s Andrew Joseph talked to dozens of experts about how the Covid-19 will play out over the next year, and he shares what he learned.
Listen: The CDC's credibility crisis & pandemic PR - STAT
This week, STAT's Helen Branswell calls in to discuss how how caving to White House pressure has eroded public trust in U.S. health agencies.
What will it take for Gilead to break even on its $21 billion deal?
The deal, which gives Gilead control of Immunomedics, came at a more than 100% premium to the latter firm's most recent stock price.
‘Carnage’ in a lab dish shows how coronavirus may damage hearts - STAT
When SARS-CoV-2 virus was added to human heart cells grown in lab dishes, the long muscle fibers that keep hearts beating were diced into short bits.
1
Damian Garde
“This is the virus itself damaging the heart. There are no other ones in that test tube. There is no systemic inflammation.”
89d
Listen: FDA intrigue, Covid-19 vaccine timelines, & editing elected officials
In this episode, Eric Topol of Scripps Research calls in to discuss his fiery criticism of FDA head Stephen Hahn and the future of the agency's reputation.